speb/financial-data huggingface dataset:
GENO.OL balance_sheet (annual, 2024-12-31) — Derivative Product Liabilities: 3216000.00
GENO.OL income_statement (annual, 2024-12-31) — Diluted Average Shares: 192245306.00
GENO.OL income_statement (annual, 2024-12-31) — Diluted EPS: 0.20
GENO.OL income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: 39182000.00
GENO.OL income_statement (annual, 2024-12-31) — EBIT: 107617000.00
GENO.OL income_statement (annual, 2024-12-31) — EBITDA: 167814000.00
GENO.OL cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: 6238000.00
GENO.OL cash_flow (annual, 2024-12-31) — End Cash Position: 281632000.00
GENO.OL cash_flow (annual, 2024-12-31) — Financing Cash Flow: 14027000.00
GENO.OL cash_flow (annual, 2024-12-31) — Free Cash Flow: 112283000.00
GENO.OL cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of PPE: -133000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Goodwill: 0.00
GENO.OL balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 319006000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Gross PPE: 264768000.00
GENO.OL income_statement (annual, 2024-12-31) — Gross Profit: 637253000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Hedging Assets Current: 0.00
GENO.OL income_statement (annual, 2024-12-31) — Interest Expense: 46960000.00
GENO.OL income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 46960000.00
GENO.OL income_statement (annual, 2024-12-31) — Interest Income: 41228000.00
GENO.OL income_statement (annual, 2024-12-31) — Interest Income Non Operating: 41228000.00
GENO.OL cash_flow (annual, 2024-12-31) — Interest Paid Cfo: -9664000.00
GENO.OL cash_flow (annual, 2024-12-31) — Interest Received Cfi: 18871000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Inventory: 234534000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Invested Capital: 901220000.00
GENO.OL cash_flow (annual, 2024-12-31) — Investing Cash Flow: -41455000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Investmentin Financial Assets: 0.00
GENO.OL balance_sheet (annual, 2024-12-31) — Investmentsin Associatesat Cost: 0.00
GENO.OL cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 0.00
GENO.OL cash_flow (annual, 2024-12-31) — Issuance Of Debt: 198160000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 77282000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Long Term Debt: 38407000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 115689000.00
GENO.OL cash_flow (annual, 2024-12-31) — Long Term Debt Issuance: 198160000.00
GENO.OL cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -155892000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Long Term Equity Investment: 0.00
GENO.OL cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: -43447000.00
GENO.OL cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 0.00
GENO.OL income_statement (annual, 2024-12-31) — Net Income: 39182000.00
GENO.OL income_statement (annual, 2024-12-31) — Net Income Common Stockholders: 39182000.00
GENO.OL income_statement (annual, 2024-12-31) — Net Income Continuous Operations: 39182000.00
GENO.OL income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 39182000.00
GENO.OL income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 39182000.00
GENO.OL cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: 39182000.00
GENO.OL income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: 39182000.00
GENO.OL cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: -2221000.00
GENO.OL income_statement (annual, 2024-12-31) — Net Interest Income: -5732000.00
GENO.OL cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: 42268000.00
GENO.OL cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: 42268000.00
GENO.OL income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: -5732000.00
GENO.OL cash_flow (annual, 2024-12-31) — Net Other Investing Changes: 1008000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Net PPE: 264768000.00
GENO.OL cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -15666000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 399383000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Non Current Deferred Revenue: 93000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Assets: 24122000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 46942000.00
GENO.OL income_statement (annual, 2024-12-31) — Normalized EBITDA: 167814000.00
GENO.OL income_statement (annual, 2024-12-31) — Normalized Income: 39182000.00
GENO.OL cash_flow (annual, 2024-12-31) — Operating Cash Flow: 130170000.00
GENO.OL income_statement (annual, 2024-12-31) — Operating Income: 63765000.00
GENO.OL income_statement (annual, 2024-12-31) — Operating Revenue: 957068000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 192245306.00
GENO.OL balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 319006000.00
GENO.OL cash_flow (annual, 2024-12-31) — Other Non Cash Items: 5732000.00
GENO.OL income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: 4406000.00
GENO.OL income_statement (annual, 2024-12-31) — Other Operating Expenses: 142962000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Other Properties: 264768000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Other Receivables: 3787000.00
GENO.OL income_statement (annual, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
GENO.OL balance_sheet (annual, 2024-12-31) — Payables: 163673000.00
GENO.OL income_statement (annual, 2024-12-31) — Pretax Income: 60657000.00
GENO.OL cash_flow (annual, 2024-12-31) — Provisionand Write Offof Assets: 49000.00
GENO.OL cash_flow (annual, 2024-12-31) — Purchase Of Business: -43447000.00
GENO.OL cash_flow (annual, 2024-12-31) — Purchase Of Intangibles: -2221000.00
GENO.OL cash_flow (annual, 2024-12-31) — Purchase Of PPE: -15666000.00
GENO.OL income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 319815000.00
GENO.OL income_statement (annual, 2024-12-31) — Reconciled Depreciation: 60197000.00
GENO.OL cash_flow (annual, 2024-12-31) — Repayment Of Debt: -155892000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Retained Earnings: 50400000.00
GENO.OL cash_flow (annual, 2024-12-31) — Sale Of PPE: 1008000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Share Issued: 192245306.00
GENO.OL income_statement (annual, 2024-12-31) — Special Income Charges: 0.00
GENO.OL cash_flow (annual, 2024-12-31) — Stock Based Compensation: 0.00
GENO.OL balance_sheet (annual, 2024-12-31) — Stockholders Equity: 718389000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Tangible Book Value: 399383000.00
GENO.OL income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
GENO.OL income_statement (annual, 2024-12-31) — Tax Provision: 21475000.00
GENO.OL income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.35